GlassScriptPhysician profile
Sandra Lombardo
NPI 1235202516
$14,494.64
in general payments reported to CMS, 2019-2025
40 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,866 · 2020: $1,357 · 2021: $880 · 2022: $1,646 · 2023: $3,324 · 2024: $4,026 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,475 · Food and Beverage: $2,136 · Education: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,475.00 |
| Food and Beverage | $2,135.79 |
| Education | $1,135.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $2,300.00 | 2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,666.28 | 2019 | |
| Beigene USA, INC. | $1,650.00 | 2023 | Brukinsa |
| Astellas Pharma US INC | $1,371.38 | 2020-2023 | Xospata |
| Exelixis INC. | $942.17 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $931.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $648.14 | 2021-2024 | Lynparza, Calquence, Imfinzi |
| Glaxosmithkline, LLC. | $642.79 | 2021-2024 | Ojjaara, Jemperli |
| Janssen Biotech, INC. | $637.47 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Seagen INC. | $557.87 | 2021-2023 | Adcetris |
| Celgene Corporation | $284.72 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Abbvie INC. | $274.84 | 2022-2025 | |
| Mirati Therapeutics, INC. | $256.63 | 2023-2024 | Krazati |
| Eisai INC. | $207.47 | 2022-2025 | |
| Lilly USA, LLC | $205.35 | 2021-2024 | Verzenio, Jaypirca |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $184.31 | 2019-2024 | Keytruda, Lynparza |
| Stemline Therapeutics INC. | $150.41 | 2024 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $145.60 | 2021-2025 | Libtayo |
| Incyte Corporation | $144.23 | 2022-2024 | Jakafi, Pemazyre |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Genentech USA, INC. | $124.68 | 2019-2023 | Columvi, Lunsumio, Polivy |
| Servier Pharmaceuticals LLC | $117.50 | 2023-2025 | |
| Amgen INC. | $113.22 | 2021-2023 | Lumakras |
| Jazz Pharmaceuticals INC. | $102.22 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Gilead Sciences, INC. | $91.34 | 2021-2023 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $89.15 | 2023-2024 | Opdivo, Augtyro |
| Pfizer INC. | $59.11 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $54.05 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $53.63 | 2023-2024 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $51.78 | 2024-2025 | Fruzaqla |
| Karyopharm Therapeutics INC. | $38.76 | 2021-2023 | Xpovio |
| Genzyme Corporation | $34.22 | 2022 | |
| Geron Corporation | $28.76 | 2025 | Rytelo |
| Progenics Pharmaceuticals, INC. | $24.26 | 2023 | Pylarify |
| Coherus Oncology, INC. | $22.41 | 2023 | |
| Amag Pharmaceuticals, INC. | $19.31 | 2019 | |
| Sobi, INC | $17.07 | 2025 | |
| Puma Biotechnology, INC. | $14.94 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lombardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.